Welcome to our dedicated page for Bluebird Bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird Bio stock.
This page aggregates historical BLUE (bluebird bio, Inc.) news, capturing the company’s evolution as a commercial-stage gene therapy business and its transition from a public to a private company. Founded in 2010 and headquartered in Somerville, Massachusetts, bluebird bio describes itself as having set the standard for gene therapy for more than a decade, with FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
News items for BLUE include corporate and transaction announcements, such as the February 21, 2025 definitive agreement to be acquired and taken private by funds managed by Carlyle and SK Capital, subsequent updates on the tender offer, regulatory approvals, and the June 2, 2025 announcement that the sale had closed and that bluebird’s common stock had ceased trading and would no longer be publicly listed.
In addition to deal-related coverage, bluebird’s releases provide context on its gene therapy platform, including references to its ex-vivo gene therapy data set, three FDA-approved therapies, and focus on access for patients, providers, and payers. Communications also highlight the company’s emphasis on safety analytics for lentiviral vector technologies and its work to expand manufacturing capacity and support treatment centers.
Investors, researchers, and industry observers can use this BLUE news feed to review the timeline of strategic decisions, financing events, and ownership changes that shaped bluebird bio’s path, as well as the company’s own description of its role in gene therapy for severe genetic diseases. Bookmark this page to quickly reference past press releases and transaction milestones associated with the former NASDAQ-listed ticker BLUE.
bluebird bio (Nasdaq: BLUE) will host a live webcast on December 7, 2020, at 7:00 p.m. ET to discuss clinical data from the 62nd American Society of Hematology Annual Meeting. Investors can join by calling (844) 825-4408 in the U.S. or +1 (315) 625-3227 internationally, using conference ID 3493595. The webcast will be accessible through the Investors & Media section of the company's website and will be available for 90 days after the event. bluebird bio focuses on gene therapies for severe genetic diseases and cancer.
bluebird bio (Nasdaq: BLUE) announced that data from its gene and cell therapy programs for sickle cell disease (SCD), transfusion-dependent beta-thalassemia (TDT), and multiple myeloma (MM) will be presented at the 62nd ASH Annual Meeting, held virtually from December 5-8, 2020. Key presentations include updated results from the Phase 1/2 HGB-206 study of LentiGlobin™ for SCD and data from multiple studies on betibeglogene autotemcel for TDT and anti-BCMA CAR T cell therapies for MM. These studies highlight improvements in health-related quality of life and long-term efficacy for treatment options.
bluebird bio (Nasdaq: BLUE) announced that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) for its investigational gene therapy, elivaldogene autotemcel (eli-cel), aimed at treating cerebral adrenoleukodystrophy (CALD), a severe neurodegenerative disorder. This therapy could be the first to use patients' own stem cells, potentially reducing immune risks. The MAA is based on data from clinical studies, including the Phase 2/3 Starbeam study. The FDA has granted eli-cel several designations, and bluebird bio aims to submit a Biologics License Application in mid-2021.
bluebird bio (NASDAQ: BLUE) announced that its management team will participate in the Jefferies Cell Therapy Virtual Summit on October 6 at 2:00 p.m. ET. Investors can access the live webcast on the bluebird bio website under the Investors & Media section. The presentation will also be available for replay for 90 days after the event. Known for pioneering gene therapy, bluebird bio focuses on severe genetic diseases and cancer, aiming to improve healthcare access and education.